889126-18-5

Upstream product

• 889126-15-2 N⁶-(3-iodobenzyl)-9-(3-amino-2,5-di-O-t-butyldimethylsilyl-3-deoxy-β-D-ribofuranosyl)adenine 
• 4461-30-7 2-chloroacetylisocyanate 
• 23345-80-4 3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose 
• 889126-05-0 5-O-acetyl-3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose 
• 889126-06-1 2,5-di-O-acetyl-3-azido-1-(6-chloropurin-9-yl)-β-D-1,3-dideoxyribofuranose 
• 889126-12-9 N⁶-(3-iodobenzyl)-9-(3-azido-2,5-di-O-t-butyldimethylsilyl-3-deoxy-β-D-ribofuranosyl)adenine 
• 179530-74-6 1,2,5-tri-O-acetyl-3-azido-3-deoxy-D-ribofuranose 

Downstream Products

• 889126-21-0 N⁶-(3-iodobenzyl)-9-(2,5-di-O-t-butyldimethylsilyl-3-deoxy-3-ureido-β-D-ribofuranosyl)adenine 

Relevant academic research and scientific papers

Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists

An alternative approach to overcome the inherent lack of specificity of conventional agonist therapy can be the reengineering of the GPCRs and their agonists. A reengineered receptor (neoceptor) could be selectively activated by a modified agonist, but no

Synthesis of 3′-ureidoadenosine analogues and their binding affinity to the A3 adenosine receptor

Novel 3′-ureidoadenosine analogues were synthesized from 1,2:5,6-di-0-isopropylidene-D-glucose in order to lead to stronger hydrogen bonding at the A3 adenosine receptor than the corresponding 3-aminoadenosine derivatives. However, all synthesi